CytoGam for CMV in solid organ transplant recipients
Part of Infections clinical trials.
This trial tests whether adding CytoGam (an antibody treatment) to standard antiviral therapy can better treat CMV (a common virus) in people who have received a solid organ transplant. It may help those with high virus levels or a new infection after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have received a solid organ transplant (like lung, heart, liver, kidney, pancreas, or intestine).
- You are taking medicine to suppress your immune system.
- You have CMV in your blood either with a high viral load (50,000 IU/mL or more) or a new infection after liver or lung transplant.
- You have not had a serious reaction to CytoGam or similar antibody treatments before.
- You are not pregnant and are not taking part in another interventional trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized immune cell treatment (CMV-specific T cells) for people whose CMV (a common herpes virus) persists or comes back after a stem cell transplant. It may help your immune system better control CMV when standard antiviral medicines aren’t fully working or can’t be used.
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
This trial tests whether an experimental drug (CMVIG) can prevent CMV infection in kidney transplant patients who are switching to or already on belatacept, a newer immunosuppressant. It may help protect those at higher risk for CMV.
This trial studies a vaccine designed to help the body fight cytomegalovirus (CMV) in children who test positive for CMV and are about to receive a donor stem cell transplant. If it works, it may reduce CMV-related illness during recovery after transplant.
This trial tests a combination of two antiviral drugs (letermovir and valganciclovir) to treat CMV infections in kidney transplant recipients. It aims to find a safer, more effective treatment option for people with active CMV after transplant.
This study uses a blood test (QuantiFERON-CMV) to help decide whether people with a silent (no symptoms) CMV infection after a solid organ transplant need treatment. If you have a low-to-moderate level of CMV in your blood without fever or organ issues, this trial may help your doctor choose the safest approach.
Hear when a new Cytomegalovirus (CMV) Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.